1398 related articles for article (PubMed ID: 19734602)
1. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
[TBL] [Abstract][Full Text] [Related]
3. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
[TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology of multiresistant Escherichia coli isolates from community-onset urinary tract infections in Cornwall, England.
Woodford N; Kaufmann ME; Karisik E; Hartley JW
J Antimicrob Chemother; 2007 Jan; 59(1):106-9. PubMed ID: 17090553
[TBL] [Abstract][Full Text] [Related]
5. A survey of plasmid-mediated fluoroquinolone resistance genes from Escherichia coli isolates and their dissemination in Shandong, China.
Xia LN; Li L; Wu CM; Liu YQ; Tao XQ; Dai L; Qi YH; Lu LM; Shen JZ
Foodborne Pathog Dis; 2010 Feb; 7(2):207-15. PubMed ID: 19911944
[TBL] [Abstract][Full Text] [Related]
6. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals.
Peirano G; Costello M; Pitout JD
Int J Antimicrob Agents; 2010 Jul; 36(1):19-23. PubMed ID: 20359869
[TBL] [Abstract][Full Text] [Related]
7. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15.
Yumuk Z; Afacan G; Nicolas-Chanoine MH; Sotto A; Lavigne JP
J Antimicrob Chemother; 2008 Aug; 62(2):284-8. PubMed ID: 18453527
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
Azap OK; Arslan H; Serefhanoğlu K; Colakoğlu S; Erdoğan H; Timurkaynak F; Senger SS
Clin Microbiol Infect; 2010 Feb; 16(2):147-51. PubMed ID: 19689464
[TBL] [Abstract][Full Text] [Related]
9. CTX-M-1-related extended-spectrum beta-lactamases producing Escherichia coli: so far a sporadic event in Western Austria.
Prelog M; Fille M; Prodinger W; Grif K; Brunner A; Würzner R; Zimmerhackl LB
Infection; 2008 Aug; 36(4):362-7. PubMed ID: 18574554
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
11. Integron-mediated ESBL resistance in rare serotypes of Escherichia coli causing infections in an elderly population of Israel.
Sompolinsky D; Nitzan Y; Tetry S; Wolk M; Vulikh I; Kerrn MB; Sandvang D; Hershkovits G; Katcoff DJ
J Antimicrob Chemother; 2005 Jan; 55(1):119-22. PubMed ID: 15574469
[TBL] [Abstract][Full Text] [Related]
12. [E. coli: resistance to quinolones and beta-lactams of clinical strains isolated in the Franche-Comté region of France].
Talon D; Lallemand-De-Conto S; Thouverez M; Bertrand X
Pathol Biol (Paris); 2004 Mar; 52(2):76-81. PubMed ID: 15001235
[TBL] [Abstract][Full Text] [Related]
13. Emergence of imipenem resistance in clinical Escherichia coli during therapy.
Oteo J; Delgado-Iribarren A; Vega D; Bautista V; Rodríguez MC; Velasco M; Saavedra JM; Pérez-Vázquez M; García-Cobos S; Martínez-Martínez L; Campos J
Int J Antimicrob Agents; 2008 Dec; 32(6):534-7. PubMed ID: 18775649
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
[TBL] [Abstract][Full Text] [Related]
15. CTX-M type extended spectrum beta-lactamases in Escherichia coli isolates from community acquired upper urinary tract infections at a university in the European part of Turkey.
Celik AD; Yulugkural Z; Kuloglu F; Eroglu C; Torol S; Vahaboğlu H; Akata F
J Microbiol Immunol Infect; 2010 Apr; 43(2):163-7. PubMed ID: 20457435
[TBL] [Abstract][Full Text] [Related]
16. CTX-M-15 extended-spectrum (beta)-lactamase from Nigerian Klebsiella pneumoniae.
Soge OO; Queenan AM; Ojo KK; Adeniyi BA; Roberts MC
J Antimicrob Chemother; 2006 Jan; 57(1):24-30. PubMed ID: 16319181
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.
Simner PJ; Zhanel GG; Pitout J; Tailor F; McCracken M; Mulvey MR; Lagacé-Wiens PR; Adam HJ; Hoban DJ;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):326-34. PubMed ID: 21353961
[TBL] [Abstract][Full Text] [Related]
19. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
